Share Prices & Company Research

Stockbroking

Hikma Pharmaceuticals

Current Price 1812.05p Bid 1817.00p Ask 1818.00p Change 2.42%
Last Updated: 19/08/2018 18:53. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Hikma Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'njectables, Generics and Branded, based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.

Financial Highlights Year Ended 31/12/2017

Turnover
£1,936.00m
Operating Profit
£-747.00m
Dividend Yield
1.26
Dividend Per Share
34.00
Dividend Cover
0.00
P/E Ratio
-5.05

Key Personnel

Sigurdur Oli Olafsson
Chief Executive Officer
Said Samih Darwazah
Executive Chairman
Mazen Samih Darwazah
Executive Vice Chairman
Dr Pamela Josephine Kirby
Non-Executive Director
Robert Mark Pickering
Non-Executive Director
Mary Regina Henderson
Non-Executive Director
Dr Jochen Gann
Non-Executive Director
John Julius Castellani
Non-Executive Director
Ali Mohammed Al-Husry
Non-Executive Director
Patrick Noel Butler
Non-Executive Director

Stock Details

EPIC
HIK
ISIN
GB00B0LCW083
Shares in Issue
241,421,135
Market cap
£4,285.23m

Analyst Views (5)

Strong Buy
 
20.00%
Buy
 
20.00%
Hold
 
40.00%
Sell
 
20.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1818.00p
Bid Price
1817.00p
Ask Price
1818.00p
Volume
1168649
Change Today
43.00p
% Change Today
2.42%
Open
1809.00p
Previous Close
1818.00p
Intraday High
1826.00p
Intraday Low
1788.50p
52 Week High
1846.00p
52 Week Low
814.20p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Hikma Pharmaceuticals Intra-day Chart

Hikma Pharmaceuticals News

News in this section is provided by MoneyAM

Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC 16 Aug 2018 | 08:30 Global equities slump on falling copper prices and mounting concerns over Turkey 15 Aug 2018 | 16:51 Weakness in the mining sector hits FTSE 15 Aug 2018 | 11:54 UK stocks open flat as Turkey contagion fears linger 15 Aug 2018 | 09:03 Hikma Pharmaceuticals ups guidance as results top expectations 15 Aug 2018 | 08:54 Broker Forecast - Numis issues a broker note on Hikma Pharmaceuticals PLC 09 Aug 2018 | 09:20 Hikma Pharmaceuticals signs drug distribution deal with Perrigo 09 Jul 2018 | 13:58 Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC 03 Jul 2018 | 08:20 Hikma Pharmaceuticals appoints Henriette Nielsen as Chief Transformation Officer 04 Jun 2018 | 09:55 Director Deals - Hikma Pharmaceuticals PLC (HIK) 30 May 2018 | 16:00 Hikma launches generic postpartum hemorrhage treatment in US 30 May 2018 | 13:05 Director Deals - Hikma Pharmaceuticals PLC (HIK) 23 May 2018 | 11:30 Broker Forecast - Numis issues a broker note on Hikma Pharmaceuticals PLC 18 May 2018 | 10:40 UK stocks open 0.2% lower as AstraZeneca disappoints 18 May 2018 | 09:03 Hikma Pharmaceuticals reiterates full-year guidance 18 May 2018 | 08:43 Director Deals - Hikma Pharmaceuticals PLC (HIK) 15 May 2018 | 15:20 Director Deals - Hikma Pharmaceuticals PLC (HIK) 15 May 2018 | 15:20 Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC 01 May 2018 | 10:00 Hikma signs agreement to distribute, market Rovi cardiovascular product 24 Apr 2018 | 10:04 Hikma launches injection to reduce severity of cardiomyopathy 20 Apr 2018 | 09:28 Hikma Pharmaceuticals subsidiary launches generic HIV treatment 20 Mar 2018 | 13:44 Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC 20 Mar 2018 | 09:50 Director Deals - Hikma Pharmaceuticals PLC (HIK) 19 Mar 2018 | 16:15 Director Deals - Hikma Pharmaceuticals PLC (HIK) 19 Mar 2018 | 16:15 Broker Forecast - Morgan Stanley issues a broker note on Hikma Pharmaceuticals PLC 15 Mar 2018 | 15:00 Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC 15 Mar 2018 | 13:50 Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC 15 Mar 2018 | 13:20 Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC 15 Mar 2018 | 12:40 Expected boost in oil output weighs on FTSE 14 Mar 2018 | 16:47 Upbeat industrial data from China boosts the resources sector 14 Mar 2018 | 11:48

Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Tangible Assets
828.0
969.0
Intangible Assets & Goodwill
785.0
1,719.0
Investments & Other Non-Current Assets
201.0
227.0
Total Non-Current Assets
1,814.0
2,915.0
Inventory
488.0
459.0
Trade & Receivables
707.0
759.0
Cash & Receivables
227.0
155.0
Other Current Assets & Assets Held for Resale
152.0
75.0
Total Assets
3,388.0
4,363.0

Liabilities (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Short Term Liabilities
797.0
918.0
Long Term Liabilities
1,063.0
1,034.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
1,860.0
1,952.0

Net Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Net Assets
1,528.0
2,411.0

Equity (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Share Capital
40.0
40.0
Minority Interests
14.0
15.0
Retained Earnings
0.0
0.0
Share Premium Account
282.0
282.0
Other Equity
1,192.0
2,074.0
Total Equity
1,528.0
2,411.0

Cashflow (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Cashflow from Operating Activities
443.0
293.0
Cashflow Before Financing
292.0
-402.0
Increase / Decrease in Cash
72.0
-383.0

Income (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Turnover
1,936.0
1,950.0
Cost of Sales
969.0
964.0
Gross Profit
967.0
986.0
Operating Profit
-747.0
302.0
Pre-Tax Profit
-738.0
210.0
Profit / Loss for the Year
-839.0
155.0

Dividend History

Data has been provided by MoneyAM

Period
Ex-Dividend Date
Payment Date
H1 Dividend
23 Aug 2018
21 Sep 2018
H2 Dividend
05 Apr 2018
24 May 2018
H1 Dividend
24 Aug 2017
22 Sep 2017
H2 Dividend
06 Apr 2017
25 May 2017
H1 Dividend
01 Sep 2016
30 Sep 2016
H2 Dividend
07 Apr 2016
19 May 2016
H1 Dividend
27 Aug 2015
25 Sep 2015
H2 Dividend
16 Apr 2015
21 May 2015
Special Dividend
27 Aug 2014
26 Sep 2014
H1 Dividend
27 Aug 2014
26 Oct 2014
Special Dividend
23 Apr 2014
22 May 2014
H2 Dividend
23 Apr 2014
22 May 2014
Special Dividend
04 Sep 2013
07 Oct 2013
H1 Dividend
04 Sep 2013
07 Oct 2013
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.